Asthma treatment options
Pro Research Analysisby 
Searched over 200M research papers
Standard Asthma Treatment Options: Inhaled Corticosteroids, Bronchodilators, and Leukotriene Antagonists
The foundation of asthma treatment for most patients is the daily use of inhaled corticosteroids (ICS), which help control airway inflammation and reduce symptoms and exacerbations Niimi2023Bertrand2020Choby2015. For patients with persistent symptoms, long-acting beta-2 agonists (LABAs) are often added to ICS therapy, and leukotriene receptor antagonists can be used as additional controller medications Niimi2023Bertrand2020Choby2015. Short-acting beta-2 agonists (SABAs) are commonly used as reliever medications during acute exacerbations Niimi2023Bertrand2020.
Stepwise Approach and Personalized Asthma Management
Asthma treatment is typically managed using a stepwise approach, where therapy is adjusted based on the severity of symptoms and the level of control achieved Niimi2023Cazzola2023. This approach allows for stepping up treatment when asthma is not well controlled and stepping down when control is maintained, aiming to use the lowest effective dose of medication Niimi2023Cazzola2023. Recent guidelines emphasize the importance of personalized treatment, considering individual patient characteristics and treatable traits to optimize outcomes .
Advanced and Add-On Therapies: Biologics and Immunotherapy
For patients with severe asthma who do not respond adequately to standard therapies, several biologic treatments have been developed. These include monoclonal antibodies targeting specific pathways involved in asthma inflammation, such as omalizumab (anti-IgE), mepolizumab and reslizumab (anti-IL-5), benralizumab (anti-IL-5R), and dupilumab (anti-IL-4R) Hearn2020Niimi2023Porcaro2019+1 MORE. These biologics have been transformative for many patients with severe asthma, reducing exacerbations and improving quality of life Hearn2020Porcaro2019Dorey-Stein2021. Allergen immunotherapy is also an option for patients with mild-to-moderate asthma and specific allergen sensitivities Niimi2023Porcaro2019Barnes2010.
Emerging Therapies: Tezepelumab and Novel Targets
Newer biologic agents, such as tezepelumab, target upstream mediators like thymic stromal lymphopoietin (TSLP) and have shown promise in reducing exacerbations and improving lung function in severe asthma . Research continues into other novel therapies, including kinase inhibitors and improved immunotherapy approaches, aiming to address unmet needs, especially in severe and difficult-to-treat asthma Barnes2010Cazzola2023.
As-Needed and SMART/MART Therapies
Recent studies support the use of as-needed therapies, including single maintenance and reliever therapy (SMART/MART), which combines ICS and LABA in a single inhaler used both for maintenance and relief. This approach has been shown to be effective in reducing exacerbations and improving disease control in both mild-to-moderate and moderate-to-severe asthma . As-needed ICS/LABA combinations are also effective and well tolerated .
Additional and Alternative Treatments
Other add-on options for asthma management include long-acting muscarinic antagonists, sustained-release theophylline, and, in select cases, bronchial thermoplasty, which has demonstrated long-term efficacy in some patients Niimi2023Niven2003. During acute exacerbations, systemic corticosteroids, short-acting muscarinic antagonists, and oxygen therapy may be used as needed Niimi2023Bertrand2020.
Consideration of Comorbidities and Triggers
Successful asthma management also involves identifying and avoiding triggers, managing comorbid conditions such as allergic rhinitis and chronic rhinosinusitis, and ensuring regular monitoring and patient education Niimi2023Bertrand2020.
Conclusion
Asthma treatment options range from standard inhaled corticosteroids and bronchodilators to advanced biologic therapies and immunotherapy for severe cases. The stepwise and increasingly personalized approach to asthma management, along with emerging therapies, continues to improve outcomes for patients across the spectrum of disease severity Hearn2020Rogliani2020Niimi2023+6 MORE.
Sources and full results
Most relevant research papers on this topic